Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Recombinant Human Growth Hormone Therapy for Childhood Trichorhinophalangeal Syndrome Type I

A Case Report

Bibliographic Data

ID15719460
AuthorsDan Huang (0009-0007-4957-4979, Children's Hospital of Zhejiang University), Jia Zhao (0000-0003-3838-0582, Shaoxing People's Hospital), Fang-Ling Xia (Children's Hospital of Zhejiang University), Chaochun Zou (0000-0002-4667-3636, Children's Hospital of Zhejiang University, corresponding author)
Year2022
Volume9
Issue10
Pages1447-1447
Publication date2022-09-22
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueChildren (JOURNAL)
Journal identifiersISSN: 2227-9067 • E-ISSN: 2227-9067
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/children9101447
PMID36291383
OpenAlexW4296848484
LanguageEN
References cited1

Trichorhinophalangeal syndrome type I (TRPS I; MIM 190350) is a rare autosomal dominant disorder of congenital malformations due to variants of the gene TRPS1. We reported on an 11-year-old Chinese boy with TRPS I. He had typical clinical findings, including sparse hair, a bulbous nose, a long philtrum, a thin upper lip, and skeletal abnormalities including cone-shaped epiphyses, shortening of the phalanges, and short stature. Trio whole exome sequencing identified a likely pathogenic heterozygous variant c.1957C > T (p.Q653*) in exon 4 of TRPS1, which has not been previously reported. He had been treated with rhGH therapy at a dose of 0.34 mg/(kg/week) at age 11, and a follow-up was conducted for one year. The rhGH therapy led to an increase in growth with a mean growth velocity of 1.12 cm/month (+1.1 SDS/year), and insulin-like growth factor 1 (IGF-1) concentration increased within normal range in our case. Moreover, we summarize 12 cases with TRPS I, including TRPS1 gene variants, growth hormone (GH) axis evaluation, IGF-1 concentration, and treatment in each analyzed case. Eight cases with TRPS I show a good response to rhGH therapy, and five of them have elevated IGF-1. Classic GH deficiency is not common among patients with TRPS I. The presence or absence of GH deficiency is not an absolute criterion for determining whether rhGH therapy should be used in TRPS I. It proves that rhGH therapy improves height outcomes before puberty in TRPS I in the short term. Effects on final adult height will need a longer follow-up and more adult-height data. The rise in IGF-1 could correlate with an increase in short-term height. Measuring IGF-1 levels is recommended as part of the assessment during the follow-up of patients with TRPS I

Biology · Bone age · Brachydactyly · Exome sequencing · Gene · Growth factor · Growth hormone · Growth hormone deficiency · Hormone · Insulin-like growth factor · Mutation · Short stature · Genetic factors in colorectal cancer · Genomic variations and chromosomal abnormalities · Genomics and Chromatin Dynamics · Medicine · Endocrinology · Genetics · Internal Medicine · Pediatrics

  • Weight-for-length/height growth curves for children and adolescents in China in comparison with body mass index in prevalence estimates of malnutrition

    Open Access•Xinnan Zong, Hui Li et al.•Annals of Human Biology•2016

Citation velocityhistorical
Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae